A new drug may be an improvement on warfarin as a treatment for people with irregular heartbeats, Scottish researchers reported last night.
The drug rivaroxaban may also be easier for patients to take – making it an improved choice, experts said.
The drugs are prescribed to cut the risk of strokes and blood clots.
The researchers at Edinburgh University led a global study involving some 14,000 patients.
Reporting in the New England Journal of Medicine, the researchers say the risk of fatal bleeding in the brain was reduced from five per thousand to two per thousand.
Researcher Professor Keith Fox said: "We know that about a third of patients eligible for warfarin are not currently receiving it. This may be because they are too frail and may not be able to manage taking the drug appropriately, with the need for blood tests and dosage levels to be monitored closely.
"This study shows that an alternative drug for patients with irregular heart beats is just as effective while also easier to prescribe and take."
Professor Peter Weissberg, medical director of the British Heart Foundation, which helped fund the research, said the study was "important".
He added: "An additional advantage is that they do not require the close monitoring that warfarin does. However, the rate at which these new drugs are introduced to patients will be determined by the extent to which regulators believe their benefits justify their additional cost."
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. Manesh R. Patel et al. New England Journal of Medicine August 10 2011 doi:10.1056/NEJMoa1009638

Leave a Reply